Dermagnostix published a preprint study integrating 727 skin transcriptomes from 390 patients across 22 non-communicable inflammatory skin diseases to identify 13 distinct molecular endotypes for psoriasis and eczema.

At Dermagnostix, we develop groundbreaking diagnostics for dermatology to advance clinical practice and improve patients’ lives. Why dermatology? • One third of the population suffers from at least one skin condition – with a strong upward trend. • Skin diseases impair patients’ quality of life more drastically than cancer and diabetes. • Biologicals and small-molecule inhibitors have created an unprecedented potential for precision medicine. Diagnostics is lagging behind. Our solution? Groundbreaking translational research meets cutting-edge technology: Dermagnostix provides unique diagnostic tests for unmet clinical needs in dermatology on a fully automated portable laboratory. With PsorX, Dermagnostix launches the first in-class molecular test for differential diagnosis of psoriasis and eczema. Get diagnostic support for hard-to-tackle skin diseases using our simple and fast system: Sample in – Answer out. www.dermagnostix.com